Hyloris annonce une date potentielle d’enregistrement pour Maxigesic® IV aux Etats-Unis
02. Mai 2023 01:00 ET
|
Hyloris Pharmaceuticals SA
- La date limite d’enregistrement a été fixée au 17 octobre 2023 par la Food & Drug Administration des États-Unis. - Le partenaire commercial exclusif de Maxigesic® IV aux États-Unis est Hikma...
Hyloris announces potential registration date for Maxigesic® IV in the US
02. Mai 2023 01:00 ET
|
Hyloris Pharmaceuticals SA
PDUFA goal date set for 17 October 2023 by U.S. Food & Drug AdministrationExclusive commercial partner for Maxigesic® IV in the U.S. is Hikma Pharmaceuticals, a leading supplier of complex,...
Analgesics Global Market Research Report 2023: A $125+ Billion market by 2027 with Focus on Codeine, Hydrocodone, Oxycodone, and Methadone
27. März 2023 10:13 ET
|
Research and Markets
Dublin, March 27, 2023 (GLOBE NEWSWIRE) -- The "Analgesics Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global analgesics market will grow from $111.15...